Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$241.07M, compared with -$43.26M a year earlier. Trailing-twelve-month EBITDA was -$349.54M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +13.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$241.07M-512.9% QoQ
- Last fiscal yearDec 2025
- -$154.59M+13.0% YoY
- LTMJun 2026
- -$349.54M-83.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -457.3% | +100.0% | +557.3 pp |
| 1 year | +13.0% | +100.0% | +87.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (154.59M) USD
- Year-over-year change
- +13.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (154.59M) | +13.0% |
| FY2024 | 2024-12-31 | (177.77M) | -147.2% |
| FY2023 | 2023-12-31 | (71.9M) | -155.7% |
| FY2022 | 2022-12-31 | (28.12M) | -45.1% |
| FY2021 | 2021-12-31 | (19.38M) | — |
EBITDA vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's LTM Jun 2026 EBITDA of -$349.54M is the 6th highest of the 7 companies compared; the peer median is -$79.65M.
- Its year-over-year change of -83.3% is the 3rd highest of 7, against a peer median of -125.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$35.03M | -30.1% | — | — | |
| LTM Mar 2026 | -$39.25M | -164.0% | — | — | |
| LTM Mar 2026 | -$52.72M | +20.1% | — | 161.1% | |
| LTM Sep 2026 | -$106.58M | -372.0% | — | 16.4% | |
| LTM Mar 2026 | -$119.51M | -312.9% | — | 597.6% | |
| LTM Jun 2026 | -$349.54M | -83.3% | — | — | |
| LTM Jun 2026 | -$393.82M | -87.1% | — | — | |
| Peer median (excluding MLYS) | -$79.65M | -125.5% | — | 161.1% | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 16.31M | 26.25M | 70.36M | 168.58M | 132.01M |
| Selling, General & Admin | 2.42M | 5.23M | 14.3M | 23.82M | 38.6M |
| Operating Expenses | 18.73M | 31.48M | 84.66M | 192.4M | 170.6M |
| Depreciation & Amortization | 0 | 0 | 0 | 43K | 59K |
| EBITDA | (19.38M) | (28.12M) | (71.9M) | (177.77M) | (154.59M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.73M) | (31.48M) | (84.66M) | (192.4M) | (170.6M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.68M | 12.76M | 14.59M | 15.95M |
| Interest Expense | 27K | 1.68M | 0 | 0 | 0 |
| Other Income / Expenses | (683K) | 1.68M | 12.76M | 14.59M | 15.95M |
| Income Before Tax | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| EPS (Diluted) | (3.89) | (5.77) | (1.99) | (3.66) | (2.29) |
| Weighted Avg Shares | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
| Weighted Avg Shares (Diluted) | 4.98M | 5.17M | 36.19M | 48.54M | 67.66M |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.